The size of the Europe Cardiac Surgery Devices Market is estimated to worth USD 0.45 billion in 2021. This value is forecasted to be growing at a CAGR of 3.06% to reach USD 0.53 billion by 2026.
A rise in the occurrence rate of diabetes, atherosclerosis, stroke, hypertension, and other chronic diseases in people's habits and adopting sedentary changes are likely to boost the cardiac surgery devices market growth in the analysis period. Owing to increasing cardiovascular diseases and the launch of wireless ECG, surgeons can monitor and identify the patient remotely, accelerating the market growth in this region over the review period. Continuous research related to cardiac failure, heart attacks, and other heart relevant ailments is projected to surge the market. Steps taken by the government organizations to increase the awareness related to cardiac surgeries are fostering the market. FDA has accepted the third-version of Abbott Laboratories, MitraClip device, which is a minimally invasive alternative to open-heart surgery for patients with leakage of mitral valves.
The cost related to the devices or the instruments at the time of heart relevant surgeries and the treatment process are so expensive that people can't afford are factors hampering the market growth. Strict rules and regulatory policies for the approval and acceptance of new devices into the market are to impede the growth in this region. The adoption of substitute surgical methods is to hinder the market.
This research report on the Europe Cardiac Surgery Devices Market has been segmented and sub-segmented into the following categories:
By Product Type:
By Application:
By Age Group:
By Country:
Regional Analysis:
Europe was the third-largest market for cardiac surgery devices in the world by the share in 2019. Factors such as the growing prevalence of heart diseases and rising healthcare expenditure are expected to drive market growth during the forecast period.
Europe is anticipated to have a significant share in the cardiac surgery devices market during the analysis period. The European market is attributed to factors like the rise in the aging population. It is predicted to have growth in requirements for surgical procedures, enhance the healthcare domain, and increase the obtainment of developed medical products. Germany is considered to lead the cardiac surgery devices market with a CAGR of 5.6% market share over the period. As per the report submitted by Eurostat, nearly 48,0 00 heart bypass surgeries were implemented in Germany. This country has registered a considerable number of operations, increasing demand for minimally invasive surgeries, and advanced technologies are expected to stimulate this region's market. France's market is projected to have notable growth in cardiac surgery devices due to increasing awareness of different diseases and the growing number of older people in the region.
Key players operating in the Europe Cardiac Surgery Devices Market profiled in this report are Trinity Biotech, Abiomed, Inc., Cardinal Health, C. R. Bard, Inc., MedWaves Incorporated, CyberHeart Incorporated, and Transmedics, Inc., among others.
1. Introduction
1.1 Market Definition
1.2 Study Deliverables
1.3 Base Currency, Base Year and Forecast Periods
1.4 General Study Assumptions
2. Research Methodology
2.1 Introduction
2.2 Research Phases
2.2.1 Secondary Research
2.2.2 Primary Research
2.2.3 Econometric Modelling
2.2.4 Expert Validation
2.3 Analysis Design
2.4 Study Timeline
3. Overview
3.1 Executive Summary
3.2 Key Inferences
3.3 Epidemology
4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
4.1 Market Drivers
4.2 Market Restraints
4.3 Key Challenges
4.4 Current Opportunities in the Market
5. Market Segmentation
5.1 Product Type
5.1.1 Cardiopulmonary Bypass Equipment
5.1.2 Beating Heart Surgery Systems
5.1.3 Perfusion Disposables
5.1.4 Cardiac Ablation Devices
5.1.5 Y-o-Y Growth Analysis, By Product Type
5.1.6 Market Attractiveness Analysis, By Product Type
5.1.7 Market Share Analysis, By Product Type
5.2 Application
5.2.1 Cardiac Arrhythmia
5.2.2 Coronary Heart Disease
5.2.3 Congenital Heart Defects
5.2.4 Congestive Heart Failure
5.2.5 Other Applications
5.2.6 Y-o-Y Growth Analysis, By Application
5.2.7 Market Attractiveness Analysis, By Application
5.2.8 Market Share Analysis, By Application
5.3 Age Group
5.3.1 New-born (0-30 days)
5.3.2 Infant (31 days-1 year)
5.3.3 Children (1-18 years)
5.3.4 Adult (18+ years)
5.3.5 Y-o-Y Growth Analysis, By Age Group
5.3.6 Market Attractiveness Analysis, By Age Group
5.3.7 Market Share Analysis, By Age Group
6. Geographical Analysis
6.1 Introduction
6.1.1 Regional Trends
6.1.2 Impact Analysis
6.1.3 Y-o-Y Growth Analysis
6.1.3.1 By Product Type
6.1.3.2 By Application
6.1.3.3 By Age Group
6.1.4 Market Attractiveness Analysis
6.1.4.1 By Product Type
6.1.4.2 By Application
6.1.4.3 By Age Group
6.1.5 Market Share Analysis
6.1.5.1 By Product Type
6.1.5.2 By Application
6.1.5.3 By Age Group
6.2 U.K
6.3 Spain
6.4 Germany
6.5 Italy
6.6 France
7. Strategic Analysis
7.1 PESTLE analysis
7.1.1 Political
7.1.2 Economic
7.1.3 Social
7.1.4 Technological
7.1.5 Legal
7.1.6 Environmental
7.2 Porter’s Five analysis
7.2.1 Bargaining Power of Suppliers
7.2.2 Bargaining Power of Consumers
7.2.3 Threat of New Entrants
7.2.4 Threat of Substitute Products and Services
7.2.5 Competitive Rivalry within the Industry
8. Market Leaders' Analysis
8.1 Trinity Biotech
8.1.1 Overview
8.1.2 Product Analysis
8.1.3 Financial analysis
8.1.4 Recent Developments
8.1.5 SWOT analysis
8.1.6 Analyst View
8.2 Abiomed, Inc.
8.3 Cardinal Health
8.4 C. R. Bard
8.5 MedWaves Incorporated
8.6 CyberHeart Incorporated
8.7 Transmedics, Inc.
9. Competitive Landscape
9.1 Market share analysis
9.2 Merger and Acquisition Analysis
9.3 Agreements, collaborations and Joint Ventures
9.4 New Product Launches
10. Market Outlook and Investment Opportunities
Appendix
a) List of Tables
b) List of Figures
Related Reports
